Table 1 Trial design characteristics
|  | n° trials |
|---|---|
Trial start | |
2012–2017 | 32 |
2017–2022 | 136 |
Recruitment status | |
Recruiting | 107 |
Not yet recruiting | 26 |
Active, not recruiting | 22 |
Completed | 13 |
Study phase | |
Phase II | 133 |
Phase III | 35 |
Funding type | |
Industry | 57 |
NIH | 21 |
All others (university, individuals, organization) | 93 |
Allocation | |
Randomized | 74 |
Non-randomized | 13 |
N/A | 81 |
Primary purpose | |
Treatment | 158 |
Diagnostic | 5 |
Prevention | 2 |
Supportive care | 2 |
Other | 1 |
Primary tumor | |
Lung cancer | 67 |
(NSCLC) | 53 |
(SCLC) | 5 |
(Not-specified) | 9 |
Breast cancer | 41 |
(Her-2 positive) | 20 |
Melanoma | 28 |
(BRAF-mutated) | 4 |
Kidney | 2 |
Primary not-Specified | 46 |
Interventions | |
Only sistemic treatments (single-associated) | 72 |
Radiotherapy alone | 44 |
Systemic treatment plus radiotherapy | 40 |
Other treatments | 1 |
Systemic treatments | |
Tyrosine kinase inhibitors | 50 |
Other target therapies | 4 |
Monoclonal antibodies (MABs) | 50 |
MABs immunotherapies target | 24 |
Chemotherapy | 20 |
Other drugs | 6 |
Radiotherapy | |
Stereotactic radiotherapy (SRS/SRT) | 47 |
Whole-brain RT (WBRT) | 27 |
Hippocampal avoidance WBRT (HA-WBRT) | 10 |
IORT | 1 |
Brachytherapy | 1 |
Technique not specified | 10 |